What is the appropriate palliative external-beam radiation regimen for a patient with urinary bladder cancer metastases to the axilla and the T11 vertebral body?

Palliative Radiation for Metastatic Bladder Cancer to Axilla and T11 Vertebra

For a patient with bladder cancer metastases to the axilla and T11 vertebral body, use external-beam radiation therapy with radiosensitizing chemotherapy for palliation, treating each metastatic site separately with appropriate dose-fractionation schedules.

Radiation Approach for Each Site

For the T11 Vertebral Metastasis (Bone Pain Control)

The most appropriate regimen depends on prognosis and treatment goals:

• Single fraction 8 Gy is the standard palliative approach for bone metastases, providing equal pain relief to multi-fraction schedules with fewer patient visits 1
• Alternative hypofractionated regimens: 20 Gy in 5 fractions or 30 Gy in 10 fractions if longer durability is desired 2
• For oligometastatic disease with good prognosis: Consider stereotactic body radiation therapy (SBRT) with doses of 24 Gy in 2 fractions, 24-27 Gy in 3 fractions, or 30-35 Gy in 5 fractions, which achieves approximately 90% local control at 1 year 3

The NCCN guidelines specifically state that external-beam radiation can be used for local palliation in patients with metastatic bladder cancer 4, 1. For spinal metastases, SBRT provides superior local control compared to conventional palliative radiation, with minimal toxicity (9.4% vertebral compression fracture risk, 0.2% neurologic injury) 3.

For the Axillary Metastasis

• Standard palliative dose: 30 Gy in 10 fractions or 20 Gy in 5 fractions for soft tissue/nodal metastases
• Treatment field: Include the gross disease with appropriate margins
• Consider SBRT if oligometastatic and patient has good performance status

Concurrent Radiosensitizing Chemotherapy

When giving palliative radiation for metastatic bladder cancer, combining radiation with radiosensitizing chemotherapy should be considered 1. However, there is a critical caveat:

• Chemotherapy should NOT be used concurrently with high-dose (>3 Gy per fraction) palliative radiation 1
• This means if using single 8 Gy or SBRT regimens, omit concurrent chemotherapy
• If using conventional fractionation (1.8-2 Gy per fraction), concurrent chemotherapy options include:
  • Cisplatin (preferred)
  • Taxane (docetaxel or paclitaxel) - Category 2B
  • 5-FU - Category 2B
  • 5-FU and mitomycin - Category 2B
  • Low-dose gemcitabine - Category 2B 1

Systemic Therapy Considerations

Since this patient has metastatic disease, they should also be receiving or considered for:

• First-line systemic therapy: Gemcitabine/cisplatin or dose-dense MVAC (Category 1) if cisplatin-eligible 1, 5
• If cisplatin-ineligible: Gemcitabine/carboplatin or immunotherapy (pembrolizumab, atezolizumab) depending on PD-L1 status 1, 5
• Maintenance therapy: Avelumab if disease stable/responding after platinum chemotherapy 6

Treatment Sequencing Algorithm

1. Assess performance status and prognosis:

   • Good PS (ECOG 0-1), limited metastases → Consider SBRT to both sites for durable control
   • Poor PS (ECOG ≥2), symptomatic → Use single 8 Gy to T11 for rapid pain relief

2. For T11 vertebral metastasis:

   • If symptomatic bone pain → 8 Gy single fraction (no concurrent chemo)
   • If oligometastatic with good prognosis → SBRT 24-27 Gy in 3 fractions (no concurrent chemo)

3. For axillary metastasis:

   • 30 Gy in 10 fractions with concurrent low-dose cisplatin or taxane
   • OR SBRT if oligometastatic

4. Coordinate with systemic therapy: Ensure patient is on appropriate first-line chemotherapy or immunotherapy

Common Pitfalls to Avoid

• Do not use concurrent chemotherapy with hypofractionated regimens >3 Gy per fraction - this significantly increases toxicity 1
• Do not treat both sites simultaneously with large fields - treat each metastatic site separately with focused fields
• Do not delay systemic therapy - palliative radiation is an adjunct, not replacement for systemic treatment in metastatic disease
• For spinal metastases, ensure proper imaging and treatment planning to avoid spinal cord toxicity, especially if considering SBRT 3

The evidence strongly supports that palliative radiation provides effective symptom control with pooled response rates of 74% for hematuria and 71% for frequency symptoms 7, and is highly effective for bone pain control 8, 9. The choice between conventional fractionation and SBRT depends on the patient's overall prognosis, performance status, and whether durable local control versus rapid symptom relief is the primary goal.